Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (520)	5/20/2003 9:23:11 AM
From: tuck	Read Replies (2) \| Respond to of 897

HMMM . . . >>8:47AM Biosite started at Underperform by Wachovia (BSTE) 51.20: Wachovia initiates coverage on Biosite with Underperform rating noting that although the BNP market is on track to grow 250% in 2003 as the blood test is quickly becoming a standard of care in congestive heart failure diagnosis and monitoring the monopoly of BSTE's BNP test is set to come to an abrupt end as Bayer (BAY) will enter the market in Q2:2003. Also Abbott (ABT) now expects to launch its BNP in US in Q1:2004. Wachovia sees valuation range of $30 to $35.<< from Briefing.com. Cheers, Tuck